Diagnostic Potential of Supplemental Static and Dynamic ⁶⁸Ga-FAPI-46 PET for Primary ¹⁸F-FDG–Negative Pulmonary Lesions

Manuel Röhrich¹⁻³, Johanna Daum^{1,3}, Ewgenija Gutjahr⁴, Anna-Maria Spektor^{1,3}, Frederik M. Glatting^{1,5,6}, Yasemin Aylin Sahin², Hans Georg Buchholz², Jorge Hoppner^{1,3}, Cathrin Schroeter^{1,3}, Eleni Mavriopoulou^{1,3}, Kai Schlamp^{3,7}, Matthias Grott^{3,8}, Florian Eichhorn^{3,8}, Claus Peter Heußel^{3,7}, Hans Ulrich Kauczor^{3,9,10}, Michael Kreuter^{11,12}, Frederik Giesel^{1,3,13–15}, Mathias Schreckenberger², Hauke Winter^{3,7} and Uwe Haberkorn^{1,3,9,16}

¹Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; ²Department of Nuclear Medicine, University Hospital Mainz, Mainz, Germany; ³German Center of Lung Research, Heidelberg, Germany; ⁴Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; ⁵Clinical Cooperation Unit Molecular and Radiation Oncology, German Cancer Research Center, Heidelberg, Germany; ⁶Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany; ⁷Department of Radiology, Thoraxklinik, University Hospital Heidelberg, Heidelberg, Germany; ⁸Department of Thoracic Surgery, Thoraxklinik, University Hospital Heidelberg, Heidelberg, Germany; ⁹Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany; ¹⁰Center for Interstitial and Rare Lung Diseases, Pneumology, and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany; ¹¹Department of Pneumology, Mainz Center for Pulmonary Medicine, Mainz University, Mainz, Germany; ¹²Medical Center and Department of Pulmonary, Critical Care, and Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany; ¹³Department of Nuclear Medicine, Medical Faculty, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany; ¹⁴Institute for Radiation Sciences, Osaka University, Osaka, Japan; ¹⁵German Cancer Consortium, Heidelberg, Germany; and ¹⁶Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany

PET using ⁶⁸Ga-labeled fibroblast activation protein (FAP) inhibitors (FAPIs) holds high potential for diagnostic imaging of various malignancies, including lung cancer (LC). However, ¹⁸F-FDG PET is still the clinical gold standard for LC imaging. Several subtypes of LC, especially lepidic LC, are frequently ¹⁸F-FDG PET-negative, which markedly hampers the assessment of single pulmonary lesions suggestive of LC. Here, we evaluated the diagnostic potential of static and dynamic ⁶⁸Ga-FAPI-46 PET in the ¹⁸F-FDG-negative pulmonary lesions of 19 patients who underwent surgery or biopsy for histologic diagnosis after PET imaging. For target validation, FAP expression in lepidic LC was confirmed by FAP immunohistochemistry. Methods: Hematoxylin and eosin staining and FAP immunohistochemistry of 24 tissue sections of lepidic LC from the local tissue bank were performed and analyzed visually. Clinically, 19 patients underwent static and dynamic ⁶⁸Ga-FAPI-46 PET in addition to ¹⁸F-FDG PET based on individual clinical indications. Static PET data of both examinations were analyzed by determining SUVmax, SUVmean, and tumor-tobackground ratio (TBR) against the blood pool, as well as relative parameters (⁶⁸Ga-FAPI-46 in relation to¹⁸F-FDG), of histologically confirmed LC and benign lesions. Time-activity curves and dynamic parameters (time to peak, slope, k_1 , k_2 , k_3 , and k_4) were extracted from dynamic ⁶⁸Ga-FAPI-46 PET data. The sensitivity and specificity of all parameters were analyzed by calculating receiver-operating-characteristic curves. Results: FAP immunohistochemistry confirmed the presence of strongly FAP-positive cancer-associated fibroblasts in lepidic LC. LC showed markedly elevated ⁶⁸Ga-FAPI-46 uptake, higher TBRs, and higher ⁶⁸Ga-FAPI-46-to-¹⁸F-FDG ratios for all parameters than did benign pulmonary lesions. Dynamic imaging analysis revealed

differential time–activity curves for LC and benign pulmonary lesions: initially increasing time–activity curves with a decent slope were typical of LC, and steadily decreasing time–activity curve indicated benign pulmonary lesions, as was reflected by a significantly increased time to peak and significantly smaller absolute values of the slope for LC. Relative ⁶⁸Ga-FAPI-46-to-¹⁸F-FDG ratios regarding SUV_{max} and TBR showed the highest sensitivity and specificity for the discrimination of LC from benign pulmonary lesions. **Conclusion:** ⁶⁸Ga-FAPI-46 PET is a powerful new tool for the assessment of single ¹⁸F-FDG–negative pulmonary lesions and may optimize patient stratification in this clinical setting.

Key Words: fibroblast activation protein; FAPI; PET; lung cancer; pulmonary lesions

J Nucl Med 2024; 00:1–8 DOI: 10.2967/jnumed.123.267103

Lung cancer (LC) is the most frequently occurring type of cancer and is associated with a high rate of cancer-related death worldwide (1). Accurate and timely diagnosis of LC is crucial for treatment stratification of patients. CT is the most frequently used imaging method for primary staging of LC. CT imaging can be supplemented by ¹⁸F-FDG PET to improve tumor staging or to further characterize suggestive pulmonary lesions. Although tumor staging is clearly improved by ¹⁸F-FDG PET compared with CT, the additional diagnostic value of ¹⁸F-FDG for characterization of suggestive pulmonary lesions is limited (2). Different subtypes of LC have been shown to exhibit largely variable ¹⁸F-FDG avidity, such as lepidic LC, which are frequently ¹⁸F-FDG–negative, or other acinar- or papillary-dominant adenocarcinomas, which are

Received Nov. 24, 2023; revision accepted Feb. 20, 2024.

For correspondence or reprints, contact Manuel Röhrich (manuel. roehrich@med.uni-heidelberg.de).

Published online Apr. 11, 2024.

COPYRIGHT © 2024 by the Society of Nuclear Medicine and Molecular Imaging.

 18 F-FDG–negative or show low 18 F-FDG avidity in a substantial percentage of cases (3,4).

PET with ⁶⁸Ga- or ¹⁸F-labeled fibroblast activation protein (FAP) inhibitors (FAPIs) has recently been introduced as a novel imaging technique for various cancers and nonmalignant diseases with tissue remodeling (5-9). Although the clinically wellestablished ¹⁸F-FDG PET is based on increased glucose metabolism of neoplastic cells, FAPI PET allows visualization of the stromal tumor compartment in terms of FAP-positive fibroblasts (9). Because of the vast stromal portion and minor neoplastic-cell portion in many epithelial tumor entities, including LC, FAPIs have a high tumor accumulation in these types of cancer (10-13). Several studies have compared the diagnostic performance of FAPI PET and ¹⁸F-FDG PET with respect to the imaging properties of both PET examinations and with respect to potential additional FAPIpositive findings that may lead to differential staging (14,15). In consideration of LC, previous studies have focused on patients with advanced LC and evaluated staging on the basis of FAPI PET compared with ¹⁸F-FDG or CT imaging (13,16-18). To our knowledge, no evaluation of FAPI PET yet exists focusing on the characterization of single suggestive pulmonary lesions in the primary situation. Here, we applied static and dynamic ⁶⁸Ga-FAPI-46 PET imaging in 19 treatment-naïve patients with ¹⁸F-FDG PET-negative suggestive pulmonary lesions. All patients underwent biopsy or surgical histologic confirmation of their lesions after imaging. For target validation, FAP expression patterns in 24 separate cases of lepidic LC were evaluated by FAP immunohistochemistry. The purpose of this analysis was to demonstrate the potential diagnostic benefit of supplemental ⁶⁸Ga-FAPI-46 PET for primary assessment of patients with single suggestive pulmonary lesions.

MATERIALS AND METHODS

Patients

Between February 2022 and April 2023, 19 patients with suggestive pulmonary lesions were examined by CT, ¹⁸F-FDG PET, and ⁶⁸Ga-FAPI-46 PET at the University Hospital Heidelberg. All patients underwent CT and ¹⁸F-FDG PET as clinical routine scans and were individually referred for additional ⁶⁸Ga-FAPI-46 PET by their treating physicians because of inconclusive findings on CT and ¹⁸F-FDG PET (¹⁸F-FDG negativity despite suggestive CT morphology or patient-related risk factors according to the Fleischner Society guide-lines (*19*). Written informed consent was obtained from all patients on an individual-patient basis following the regulations of the German Pharmaceuticals Act §13(2b). After imaging, all patients underwent resection or biopsy of their pulmonary lesions followed by histopathologic diagnosis. Retrospective analysis of imaging, clinical, and pathologic data was approved by the local institutional review board (study number S-115/2020).

Diagnostic CT, ¹⁸F-FDG PET/CT, and ⁶⁸Ga-FAPI-46 PET

All 19 patients underwent diagnostic contrast-enhanced CT imaging of the chest before PET imaging. ¹⁸F-FDG PET/CT was performed according to standard care as previously described (*14*). ⁶⁸Ga-FAPI-46 was synthesized and labeled according to established protocols (*9*). Static and dynamic ⁶⁸Ga-FAPI-46 PET/CT was performed using a Biograph mCT Flow scanner (Siemens) as previously described (*20*). In short, after injection of 187–329 MBq of ⁶⁸Ga-labeled FAPI-46, low-dose CT without contrast medium was performed, followed by dynamic PET (28 frames over 60 min) to characterize tracer uptake over time, followed by whole-body PET/CT 60 min after tracer injection in 16 of 19 patients. In 3 patients, only whole-body PET/CT 60 min after tracer injection was performed. Reconstructions were performed with corrections for scatter, decay, and attenuation. The average time (±SD) between $^{18}\text{F-FDG}$ PET/CT and $^{68}\text{Ga-FAPI-46}$ PET/CT was 6.2 \pm 6.4 d.

Image Analysis

For static ¹⁸F-FDG PET/CT and ⁶⁸Ga-FAPI-46 PET/PET/CT data, all pulmonary lesions were contoured manually on the basis of their CT appearance. For all lesions, SUV_{max}, SUV_{mean}, and tumor-to-background ratio (TBR) against blood pool, as well as relative parameters (⁶⁸Ga-FAPI-46 in relation to¹⁸F-FDG), were calculated. All cases selected for this analysis were classified as ¹⁸F-FDG–negative according to lesional ¹⁸F-FDG uptake equal to or below the blood pool level (in terms of a maximum and mean TBR of less than 1.3) as previously published (*21*). Differences between histologically confirmed LC and benign lesions were analyzed. For dynamic ⁶⁸Ga-FAPI-46 PET data, time–activity curves and quantitative dynamic parameters (time to peak [time between start of the dynamic image acquisition and the frame with the highest activity] and slope [relative gradient between the time–activity curve peak and the lowest activity of the following time–activity curve section in analogy to



FIGURE 1. FAP expression in lepidic LC. (A and B) Representative hematoxylin and eosin staining (left) and immunohistochemical staining against FAP (right) of central part of lepidic LC biopsy, which shows strong stromal FAP positivity (A), and tumor front of lepidic LC, showing transition from FAP-positive LC tumor rim into FAP-negative physiologic lung tissue (B) (magnification: upper rows, ×10; lower rows, ×40) (scale bars: upper rows, 100 μ m; lower rows, 20 μ m).

TNM stage	Not applicable	Not applicable	T1cN0M0	Not applicable	T1bN0M0	T1cN0M0	Not applicable	T1bN0M0	T1cN0M0	T1bN1M0	Not applicable	Not applicable	T2aN0M0	T1bN0M0	T1cN0M0	T1bN0M0	T2aN0M0	T1aN0M0	Not applicable
Growth pattern	Not applicable	Not applicable	Lepidic	Not applicable	Acinar/lepidic	Acinar	Not applicable	Acinar	Acinar	Acinar	Not applicable	Not applicable	Acinar	Acinar	Lepidic	Not applicable	Lepidic/acinar	Lepidic	Not applicable
Diagnosis	Tuberculosis	Calcified lymph node	Adenocarcinoma	Granuloma	Adenocarcinoma	Adenocarcinoma	Sarcoidosis	Adenocarcinoma	Adenocarcinoma	Adenocarcinoma	Hamartoma	Hamartoma	Adenocarcinoma	Adenocarcinoma	Adenocarcinoma	Typical carcinoid	Adenocarcinoma	Adenocarcinoma	Lung tissue
Histologic confirmation	Wedge resection	Bronchoscopy with biopsy	Lobectomy	Wedge resection	Lobectomy	Lobectomy	Lobectomy	CT-guided biopsy	Lobectomy	CT-guided biopsy	Wedge resection	Enucleation	Lobectomy	Lobectomy	Lobectomy	CT-guided biopsy	CT-guided biopsy	Segment resection	CT-guided biopsy
Largest diameter (mm)	20	14	29	10	16	23	79	13	17	15	17	16	16	23	29	18	29	28	15
Localization	Right upper lobe	Left hilus	Right lower lobe	Right upper lobe	Left lower lobe	Left lower lobe	Right lower lobe	Left upper lobe	Right lower lobe	Right upper lobe	Left lower lobe	Right lower lobe	Right upper lobe	Left upper lobe	Right upper lobe	Right lower lobe	Right upper lobe	Left upper lobe	Left lower lobe
Dynamic PET imaging	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes
Sex	Σ	Σ	ш	Σ	Σ	ш	Σ	Σ	ш	Σ	Σ	Σ	Σ	Σ	Σ	Σ	ш	ш	Σ
Age (y)	64	73	68	58	75	70	62	50	57	63	41	45	70	72	65	50	51	64	77
Patient no.	-	N	ი	4	5	9	7	80	6	10	11	12	13	14	15	16	17	18	19

TABLE 1 Clinical Parameters and Diagnoses of 19 Patients with ¹⁸F-FDG-Negative Pulmonary Lesions previously published dynamic PET data analyses (22)]) were extracted, and differences between histologically confirmed LC and benign lesions were analyzed. All image analysis was performed using PMOD software (version 4.1; PMOD Technologies).

Immunohistochemistry

To validate FAP expression in lepidic LC, 24 tissue sections of histo-

logically proven lepidic LC from the local tissue bank were stained for hematoxylin and eosin and FAP. These 24 cases were not examined by 68Ga-FAPI-46 PET/CT. For FAP immunohistochemistry, semithin tissue sections of 4-µm thickness were prepared from corresponding paraffin blocks being generated from resection tissue after its fixation in 4% buffered formalin for 24 h at room temperature. Tissue sections were treated with cell conditioning 2 (Roche) buffer (pH 8.0) for antigen retrieval. Immunohistochemical staining was performed using the antibody anti-FAP-a (1:100; Abcam [catalog no. ab207178]). Automated immunostaining was done using the automated Ventana BenchMark Ultra with the OptiView DAB Kit (Roche), Dako Autostainer-Link 48, and the EnVision Flex Kit (Agilent). Stained tissue sections were mounted with Consul-Mount (Thermo Fisher Scientific) and scanned by Aperio AT2 (Leica; magnification 1:400) for analysis. All samples were provided by the Tissue Bank of the National Center for Tumor Diseases, in accordance with the regulations of the tissue bank and the approval of the ethics committee of Heidelberg University.

Statistical Analysis

We performed descriptive analyses for patients and their characteristics. For determination of static and dynamic PET parameters, median and range were used. For determination of significance, a 2-sided *t* test was used, and *P* values of less than 0.05 were defined as statistically significant. Receiver-operatingcharacteristic curves and corresponding estimates of area under the curve, including 95% CIs, were computed for static and dynamic PET parameters. GraphPad Prism, version 10, was used for all statistical analyses.

RESULTS

Target Confirmation of FAP in Lepidic LC

To evaluate FAP expression in lepidic LC, we performed FAP immunohistochemistry of 24 biopsy samples of lepidic LC. In all samples, we found variably intensive FAPpositive areas. FAP positivity was particularly pronounced in stroma-rich tumor areas (Fig. 1A) but was also clearly detectable in the tumor rim within single alveolar septa, which showed a desmoplastic reaction to the tumor (Fig. 1B). In contrast, adjacent lung tissue was fully FAP-negative (Fig. 1B).

Patient Characteristics and Histologic Results

The cohort consisted of 19 patients (5 female, 14 male) aged from 41 to 77 y (average, 61.8 ± 10.5 y). The average size of the CT-graphically suggestive lesions was 22.47 ± 14.9 mm. After ¹⁸F-FDG and ⁶⁸Ga-FAPI-46 PET imaging, tissue from all patients was obtained by either biopsy or surgery and subjected to definitive pathologic diagnosis. Seven patients had benign diagnoses





(2 hamartomas, 1 tuberculosis, 1 sarcoidosis, 1 granuloma, 1 calcified lymph node, and 1 lung tissue without evidence of pathology), and 12 patients were diagnosed with LC (11 adenocarcinomas [4 of them with a predominantly lepidic growth pattern] and 1 typical carcinoid). Detailed patientwise information on the clinical status and applied imaging methods is given in Table 1.

CT Size and ¹⁸F-FDG and ⁶⁸Ga-FAPI-46 Uptake of LC and Benign Lesions

LC and benign lesions showed no significant differences in their average CT size or ¹⁸F-FDG uptake in terms of SUV_{max}, SUV_{mean}, or corresponding TBR (Figs. 2A and 2B). In contrast, the average ⁶⁸Ga-FAPI-46 uptake of LC lesions was significantly higher than that of benign lesions (Fig. 2C). Similarly, ratios between ⁶⁸Ga-FAPI-46 uptake and ¹⁸F-FDG uptake were also significantly higher in LC than



FIGURE 3. Example ¹⁸F-FDG and ⁶⁸Ga-FAPI-46 images of 51-y-old woman with adenocarcinoma with lepidic growth pattern in right upper lobe. (A) Maximum-intensity-projection PET images. (B) Axial images of suggestive lesion (red arrows) with low CT density in right lower lobe. Green arrows show blood pool in aortic arch. Lesion had ¹⁸F-FDG uptake below blood pool niveau but was strongly ⁶⁸Ga-FAPI-46-positive. CT-guided biopsy led to pathologic diagnosis of adenocarcinoma, and patient was treated by stereotactic body radiation therapy because of functional inoperability. HU = Hounsfield units.

in benign lesions (Fig. 2D). With respect to benign subentities, moderately higher ¹⁸F-FDG and ⁶⁸Ga-FAPI-46 uptake was seen in sarcoidosis, tuberculosis, and the calcified lymph node than in the other benign lesions (Supplemental Fig. 1; supplemental materials are available at http://jnm.snmjournals.org). Supplemental Table 1 provides a lesionwise overview of all static PET parameters (SUV_{max}, SUV_{mean}, and corresponding TBR for ¹⁸F-FDG and ⁶⁸Ga-FAPI-46 PET) for all LC and benign lesions analyzed. Figures 3 and 4 show ¹⁸F-FDG PET and ⁶⁸Ga-FAPI-46 images of an example patient with a lepidic LC that had ¹⁸F-FDG uptake below the blood pool level and strong ⁶⁸Ga-FAPI-46 positivity (Fig. 3) and an example patient with a hamartoma that showed only faint uptake of both tracers (Fig. 4).

Dynamic ⁶⁸Ga-FAPI-46 PET Imaging Characteristics of LC and Benign Lesions

Dynamic ⁶⁸Ga-FAPI-46 PET imaging was performed on 11 patients with LC and 5 patients with benign lesions. LC and benign



FIGURE 4. Example ¹⁸F-FDG and ⁶⁸Ga-FAPI-46 images of 41-y-old man with hamartoma in left lower lobe. (A) Maximum-intensity-projection PET images. (B) Axial images of suggestive lesion (arrows) in left lower lobe. After wedge resection, hamartoma was diagnosed by pathology. HU = Hounsfield units.

lesions showed marked differences regarding their time–activity curves characteristics. As shown by the averaged time–activity curves in Figure 5A, LC was characterized by a delayed peak at 500–1,000 s after injection followed by a slow, continuous washout phase. In contrast, benign lesions typically showed an early peak within the first 2 min after injection followed by a rapid washout phase resulting in a reduction in activity to approximately 50% at 60 min after injection. Quantitative analysis of time to peak and slope showed a significantly prolonged time to peak and slope showed a significantly prolonged time to peak and significantly smaller absolute values of slopes for LC than for benign lesions (Fig. 5B). Figure 5C shows 2 cases of LC and sarcoidosis, both of which had intermediate ⁶⁸Ga-FAPI-46 uptake on static imaging but time–activity curves typical of LC and benign lesions, respectively.

Sensitivity and Specificity of Static and Dynamic ⁶⁸Ga-FAPI-46 PET Imaging Parameters

Receiver-operating-characteristic curves calculated for all static parameters and for the dynamic parameters time to peak and slope



FIGURE 5. Dynamic ⁶⁸Ga-FAPI-46 PET imaging properties of LC and benign pulmonary lesions. (A) Averaged time-activity curves (relative to peak) of LC and benign pulmonary lesions. (B) Box plot of time to peak and slope of LC and benign pulmonary lesions. Boxes represent interquartile range, whiskers represent interquartile range of 1.5, and horizontal line within box indicates median. (C) Representative cases: 63-y-old man with adenocarcinoma (arrow) of left upper lobe and 62-y-old man with focally ⁶⁸Ga-FAPI-46-avid sarcoid mass (encircled) in right lower lobe. Images are from static PET, and time-activity curves are from dynamic PET. Although both lesions show intermediate ⁶⁸Ga-FAPI-46 uptake, time-activity curves clearly differ, with delayed peak of LC and markedly pronounced slope of sarcoidosis. *P < 0.05.

showed high sensitivity and specificity for discriminating LC from benign lesions. The highest areas under the curve were calculated for ⁶⁸Ga-FAPI-46/¹⁸F-FDG SUV_{max} TBR (0.9167), ⁶⁸Ga-FAPI-46/¹⁸F-FDG SUV_{mean} (0.9167), SUV_{mean} TBR (0.8831), and SUV_{max} TBR (0.8571) (Fig. 6). The calculated sensitivity and specificity of ⁶⁸Ga-FAPI-46/¹⁸F-FDG SUV_{max} TBR were 85.71 (95% CI, 48.69–99.27) and 83.33 (95% CI, 55.20–97.04), respectively, for a cutoff of 1.62. The other static and the dynamic ⁶⁸Ga-FAPI-46 PET parameters showed slightly lower areas under the curve, and the ¹⁸F-FDG PET parameters and CT size showed significantly lower areas under the curve (Supplemental Fig. 2).

DISCUSSION

This retrospective analysis evaluated the ⁶⁸Ga-FAPI-46 uptake of primary, ¹⁸F-FDG-negative LC and benign pulmonary lesions, as well as their kinetic behavior in dynamic ⁶⁸Ga-FAPI-46 PET imaging. To characterize lepidic LC as a particularly promising ¹⁸F-FDG-negative target for ⁶⁸Ga-FAPI-46 PET, we performed additional FAP immunohistochemistry of 24 tissue sections of lepidic LC and found strong FAP positivity in all specimens. This advance target characterization was of crucial interest for our analysis, as the presence of cancer-associated fibroblasts in lepidic LC has already been described histologically but the FAP expression of this entity had not, to our knowledge, been evaluated before (23). The strong FAP expression of lepidic LC is noteworthy because FAP-positive cancer-associated fibroblasts are crucially involved in tumor desmoplasia (24,25)-a process that is canonically considered a feature of more invasive LC subtypes, but not lepidic LC, as recently proposed by the International Association for the Study of Lung Cancer pathology committee (26). However, the results of our immunohistochemical and PET studies seem to indicate that a stromal reaction resulting in FAP positivity of the tumors is present even in early-stage, relatively noninvasive cancers such as lepidic LC.

In our analysis, all cases of LC showed markedly elevated ⁶⁸Ga-FAPI-46 uptake, increased TBRs, and increased ⁶⁸Ga-FAPI-46/18F-FDG ratios for all parameters compared with benign pulmonary lesions. One prospective study and large retrospective analyses have demonstrated that ⁶⁸Ga-FAPI-46 PET in addition to gold standard imaging methods holds high potential for the staging and clinical management of LC (13-15,27). However, these studies were focused on advanced-stage cancers and did not address the value of ⁶⁸Ga-FAPI-46 PET for the assessment of unclear single pulmonary lesions. In their recent prospective study on 34 patients with advanced, metastatic LC, Wang et al. showed that ⁶⁸Ga-FAPI PET in addition to ¹⁸F-FDG PET/CT detects additional suspected metastases in lymph nodes, brain, bone, and pleura. However, the metabolic tumor volume and SUV_{max} in primary and recurrent primaries were mostly identical for both tracers (13). Similarly, Giesel et al. found no significant difference in ⁶⁸Ga-FAPI and ¹⁸F-FDG uptake by primary tumors in 71 patients with various cancers, including 9 patients with LC (14). The missing difference in ¹⁸F-FDG and ⁶⁸Ga-FAPI PET signal behavior for LC primaries in these studies might be explained by the inclusion of patients with primary and recurrent stage IV disease only, which is biologically more aggressive and more ¹⁸F-FDG-avid than the nonmetastatic ¹⁸F-FDG-negative primaries in our analysis. Chen et al. analyzed ⁶⁸Ga-FAPI- and ¹⁸F-FDG-based staging of 54 cancer patients, including 8 with LC, and reported higher SUVs for LC primaries for ⁶⁸Ga-FAPI than for ¹⁸F-FDG. Furthermore, they



FIGURE 6. Receiver-operating-characteristic (ROC) curves of 4 quantitative PET parameters with highest discriminatory power: ⁶⁸Ga-FAPI-46/¹⁸F-FDG SUV_{max} (A), ⁶⁸Ga-FAPI-46/¹⁸F-FDG TBR SUV_{max} (B), SUV_{mean} TBR (C), and SUV_{max} TBR (D).

included 2 LC cases in which the primary tumor was detectable with ⁶⁸Ga-FAPI PET but not ¹⁸F-FDG PET (*15*). However, because only 2 stage I LC cases were included, there is reduced comparability between their results and ours.

Dynamic imaging analysis revealed differential time–activity curves for LC and benign pulmonary lesions: initially increasing time–activity curves with a decent slope were typical of LC, and steadily decreasing time–activity curve indicated benign pulmonary lesions, as reflected by a significantly increased time to peak and absolute value of the slope for LC. These results are in line with our previously published data on dynamic ⁶⁸Ga-FAPI-46 PET in LC and fibrosing interstitial lung diseases, intraductal papillary mucinous neoplasms of the pancreas, and pancreatic ductal adenocarcinomas. In that work, we observed similar time–activity curve patterns related to whether tumors were benign or malignant (*20,28*). On the basis of our summed experiences, we would generally recommend dynamic ⁶⁸Ga-FAPI PET acquisition in primary patients with unclear and potentially malignant lesions, such as screening-detected pulmonary lesions.

Relative (⁶⁸Ga-FAPI-46/¹⁸F-FDG) SUV_{max} and TBR showed the highest sensitivity and specificity for the discrimination of LC from benign pulmonary lesions, and the other static and dynamic PET parameters had only slightly lower sensitivity and specificity. CT size, which is in general the most important imaging feature for the risk stratification of pulmonary lesions (29,30), showed significantly lower sensitivity and specificity for the discrimination of LC from benign lesions, as can be explained by the relatively low number of patients included. The sensitivity and specificity of the ⁶⁸Ga-FAPI-46 PET–derived parameters calculated for our dataset were similar to those reported for ¹⁸F-FDG (31,32). However, as our dataset included only highly selected ¹⁸F-FDG–negative cases, a comparison between the discriminatory power of ⁶⁸Ga-FAPI-46 PET and ¹⁸F-FDG PET for single pulmonary lesions cannot be made.

Our results suggest that supplemental ⁶⁸Ga-FAPI-46 PET may improve the noninvasive assessment of primary pulmonary lesions compared with 18F-FDG PET and CT alone. Noninvasive assessment of pulmonary lesions is of great clinical relevance because there are several contraindications, such as coagulopathies, reduced cardiopulmonary function, or reduced lung function, that can disfavor surgery or biopsy interventions, especially in elderly patients (33). In particular, for lepidic LC, 68Ga-FAPI-46 PET holds great potential to facilitate and accelerate clinical decision making toward biopsy or operative resection, as ¹⁸F-FDG PET frequently leads to inconclusive results, and CT-morphologic progression of these slowly growing tumors can be detected only over a relatively long time (34). On the other hand, supplemental ⁶⁸Ga-FAPI-46 PET could be helpful to avoid overtreatment in terms of unnecessary resections, as doublenegative (¹⁸F-FDG and ⁶⁸Ga-FAPI-46) lesions appear to have a high probability of being benign. Dynamic imaging can support the assessment of pulmonary lesions in cases without clearly suggestive high or low ⁶⁸Ga-FAPI-46 uptake. However, the results of our recent analysis should be considered preliminary and hypothesis-generating, and 2 major limitations must be mentioned. First, the number of patients analyzed was relatively small-with the subgroups thus being even smaller, especially with regard to benign subentities. Second, because the patients were highly selected according to ¹⁸F-FDG negativity of suggestive pulmonary lesions, our dataset does not allow comparison of the diagnostic accuracy of ¹⁸F-FDG and ⁶⁸Ga-FAPI-46 PET for primary pulmonary lesions in general. Larger, confirmative studies are necessary to gain more evidence on the clinical value of ⁶⁸Ga-FAPI-46 PET for assessment of primary pulmonary lesions.

CONCLUSION

The intense ⁶⁸Ga-FAPI-46 uptake of primary, ¹⁸F-FDG–negative LC compared with benign pulmonary lesions, as well as their differential kinetic behavior on dynamic ⁶⁸Ga-FAPI-46 PET imaging, suggests that supplemental ⁶⁸Ga-FAPI-46 PET may optimize patient stratification in this clinical scenario. The promising results of this analysis should be confirmed by larger studies.

DISCLOSURE

This work was funded by the Federal Ministry of Education and Research (grant 13N 13341). Uwe Haberkorn has filed a patent application for quinoline-based FAP-targeting agents for imaging and therapy in nuclear medicine and has shares of a consultancy group for iTheranostics. No other potential conflict of interest relevant to this article was reported.

KEY POINTS

QUESTION: Can supplemental ⁶⁸Ga-FAPI-46 PET help to assess ¹⁸F-FDG-negative single pulmonary lesions?

PERTINENT FINDINGS: LC showed markedly elevated ⁶⁸Ga-FAPI-46 uptake, increased TBRs, and increased ⁶⁸Ga-FAPI-46/¹⁸F-FDG ratios for all parameters compared with benign pulmonary lesions. Dynamic imaging analysis revealed differential time–activity curves for LC and benign pulmonary lesions. Relative (⁶⁸Ga-FAPI-46/¹⁸F-FDG) SUV_{max} and TBR showed the highest sensitivity and specificity for discrimination of LC from benign pulmonary lesions.

IMPLICATIONS FOR PATIENT CARE: Supplemental ⁶⁸Ga-FAPI-46 PET appears extremely promising in the clinical scenario of ¹⁸F-FDG–negative single pulmonary lesions, especially when biopsy or resection is hampered by reduced health status of patients and noninvasive methods are crucial for assessment of malignancy.

REFERENCES

- Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. *Clin Chest Med.* 2020;41:1–24.
- Ruilong Z, Daohai X, Li G, Xiaohong W, Chunjie W, Lei T. Diagnostic value of ¹⁸F-FDG-PET/CT for the evaluation of solitary pulmonary nodules: a systematic review and meta-analysis. *Nucl Med Commun.* 2017;38:67–75.
- Lococo F, Guerrera F, Rena O, et al. Accuracy of ¹⁸F-FDG in detecting stage I lung adenocarcinomas according to IASLC/ATS/ERS classification. *Heart Lung Circ.* 2022;31:726–732.
- Nakamura H, Saji H, Shinmyo T, et al. Close association of IASLC/ATS/ERS lung adenocarcinoma subtypes with glucose-uptake in positron emission tomography. *Lung Cancer*. 2015;87:28–33.
- Kratochwil C, Flechsig P, Lindner T, et al. ⁶⁸Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–805.
- Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. *Radiology*. 2023;306:e220749.
- Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59: 1415–1422.
- Loktev A, Lindner T, Burger EM, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. *J Nucl Med.* 2019;60: 1421–1429.
- Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancerassociated fibroblasts. J Nucl Med. 2018;59:1423–1429.
- Röhrich M, Syed M, Liew DP, et al. ⁶⁸Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas: imaging analysis and histological validation. *Radiother Oncol.* 2021;160:192–201.

- Röhrich M, Naumann P, Giesel FL, et al. Impact of ⁶⁸Ga-FAPI PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. *J Nucl Med.* 2021;62:779–786.
- Giesel FL, Adeberg S, Syed M, et al. FAPI-74 PET/CT using either ¹⁸F-AlF or Cold-Kit ⁶⁸Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. *J Nucl Med.* 2021;62:201–207.
- Wang L, Tang G, Hu K, et al. Comparison of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT in the evaluation of advanced lung cancer. *Radiology*. 2022;303:191–199.
- Giesel FL, Kratochwil C, Schlittenhardt J, et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT in cancer patients. *Eur J Nucl Med Mol Imaging*, 2021;48:4377–4385.
- Chen H, Pang Y, Wu J, et al. Comparison of [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. *Eur J Nucl Med Mol Imaging*. 2020;47:1820–1832.
- Koerber SA, Rohrich M, Walkenbach L, et al. Impact of ⁶⁸Ga-FAPI PET/CT on staging and oncologic management in a cohort of 226 patients with various cancers. J Nucl Med. 2023;64:1712–1720.
- Zhou X, Wang S, Xu X, et al. Higher accuracy of [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT comparing with 2-[¹⁸F]FDG PET/CT in clinical staging of NSCLC. Eur J Nucl Med Mol Imaging. 2022;49:2983–2993.
- Wei Y, Ma L, Li P, et al. FAPI compared with FDG PET/CT for diagnosis of primary and metastatic lung cancer. *Radiology*. 2023;308:e222785.
- Bueno J, Landeras L, Chung JH. Updated Fleischner Society guidelines for managing incidental pulmonary nodules: common questions and challenging scenarios. *Radiographics*. 2018;38:1337–1350.
- Röhrich M, Leitz D, Glatting FM, et al. Fibroblast activation protein-specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study. J Nucl Med. 2022;63:127–133.
- Cheran SK, Nielsen ND, Patz EF Jr. False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. AJR. 2004;182:1129–1132.
- Maurer GD, Brucker DP, Stoffels G, et al. ¹⁸F-FET PET imaging in differentiating glioma progression from treatment-related changes: a single-center experience. J Nucl Med. 2020;61:505–511.
- Yotsukura M, Asamura H, Suzuki S, et al. Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma. *Lung Cancer.* 2020;145:158–166.
- Zeltz C, Primac I, Erusappan P, Alam J, Noel A, Gullberg D. Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins. *Semin Cancer Biol.* 2020;62:166–181.
- Lo A, Wang LS, Scholler J, et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. *Cancer Res.* 2015;75:2800–2810.
- 26. Thunnissen E, Beasley MB, Borczuk A, et al. Defining morphologic features of invasion in pulmonary nonmucinous adenocarcinoma with lepidic growth: a proposal by the International Association for the Study of Lung Cancer pathology committee. J Thorac Oncol. 2023;18:447–462.
- Koerber SA, Rohrich M, Walkenbach L, et al. Impact of ⁶⁸Ga-FAPI PET/CT on staging and oncologic management in a cohort of 226 patients with various cancers. J Nucl Med. 2023;64:1712–1720.
- Lang M, Spektor AM, Hielscher T, et al. Static and dynamic ⁶⁸Ga-FAPI PET/CT for the detection of malignant transformation of intraductal papillary mucinous neoplasia of the pancreas. *J Nucl Med.* 2023;64:244–251.
- Chen B, Li Q, Hao Q, et al. Malignancy risk stratification for solitary pulmonary nodule: a clinical practice guideline. *J Evid Based Med.* 2022;15:142–151.
- Mazzone PJ, Lam L. Evaluating the patient with a pulmonary nodule: a review. JAMA. 2022;327:264–273.
- Groheux D, Quere G, Blanc E, et al. FDG PET-CT for solitary pulmonary nodule and lung cancer: literature review. *Diagn Interv Imaging*. 2016;97:1003–1017.
- Cronin P, Dwamena BA, Kelly AM, Carlos RC. Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. *Radiology*. 2008;246:772–782.
- Young M, Sankari A. Percutaneous lung lesion biopsy. StatPearls website. https:// www.statpearls.com/point-of-care/30515. Updated February 14, 2024. Accessed March 20, 2024.
- Hong JH, Park S, Kim H, et al. Volume and mass doubling time of lung adenocarcinoma according to WHO histologic classification. *Korean J Radiol.* 2021;22: 464–475.